Insider trading

Period: 120 months Stock: ARWR Plan: Not on a plan × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

160 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

160 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

160 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

160 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
160 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
160 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

160 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
18 Aug 2026
PERRY MICHAEL S Director
Sold at will
$1.01M 11,600 at 87.30
9.4%
Not planned
18 Aug 2026
Sold at will
$173.92K 2,000 at 86.96
6.0%
Not planned
17 Dec 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will 4×
$5.44M 85,000 at 64.04
2.2%
Not planned
16 Dec 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will 9×
$3.40M 54,298 at 62.58
1.4%
Not planned
15 Dec 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will 3×
$8.95M 130,000 at 68.85
3.2%
Not planned
5 Dec 2025
PERRY MICHAEL S Director
Sold at will
$991.74K 16,250 at 61.03
12.4%
Not planned
28 Nov 2025
Ferrari Mauro Director
Sold at will
$493.41K 8,750 at 56.39
11.3%
Not planned
11 Apr 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will
$583.69K 50,800 at 11.49
1.3%
Not planned
10 Apr 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will
$543.50K 50,000 at 10.87
1.2%
Not planned
9 Apr 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will 3×
$406.14K 40,322 at 10.07
1.0%
Not planned
13 Mar 2025
Anzalone Christopher Richard Chief Executive Officer
Sold at will
$774.97K 51,425 at 15.07
1.3%
Not planned
1 Apr 2024
Hamilton James C Chief Discovery/Trans Medicine
Sold at will
$168.18K 6,000 at 28.03
2.8%
Not planned
20 Mar 2024
Lu Hongbo Director
Bought
$27.50K 1,000 at 27.50
3.1%
19 Mar 2024
Lu Hongbo Director
Bought
$28.00K 1,000 at 28.00
3.2%
Largest buy in 3 yrs
18 Mar 2024
Lu Hongbo Director
Bought
$27.49K 1,000 at 27.49
3.3%
First buy on file
6 Mar 2024
Myszkowski Kenneth Allen Chief Financial Officer
Sold at will
$1.41M 40,000 at 35.19
9.1%
Not planned
28 Sep 2023
Sold at will
$40.81K 1,550 at 26.33
6.7%
Not planned
18 Sep 2023
Anzalone Christopher Richard Chief Executive Officer
Sold at will 2×
$1.62M 57,755 at 28.12
1.5%
Not planned
3 Jul 2023
Oliver Tracie Chief Commercial Officer
Sold at will
$315.14K 8,925 at 35.31
12.7%
Not planned
30 Jun 2023
Hamilton James C Chief Discovery/Trans Medicine
Sold at will
$106.59K 3,000 at 35.53
1.6%
Not planned
27 Jun 2023
Myszkowski Kenneth Allen Chief Financial Officer
Sold at will
$543.00K 15,000 at 36.20
3.8%
Not planned
5 May 2023
GIVEN DOUGLAS B Director
Sold at will
$265.85K 6,500 at 40.90
5.2%
Not planned
4 May 2023
Anzalone Christopher Richard Chief Executive Officer
Sold at will 2×
$1.98M 50,000 at 39.52
1.3%
Not planned
3 May 2023
Anzalone Christopher Richard Chief Executive Officer
Sold at will
$2.15M 54,928 at 39.14
1.4%
Not planned
3 Mar 2023
Sold, plan not stated
$370.58K 11,350 at 32.65
59.1%
Sold half or more
27 Feb 2023
GIVEN DOUGLAS B Director · indirect
Sold, plan not stated
$28.54K 875 at 32.62
6.3%
9 Jan 2023
Sold, plan not stated
$96.00K 3,200 at 30.00
10.0%
5 Jan 2023
O'Brien Patrick COO and General Counsel
Sold, plan not stated 2×
$560.85K 15,000 at 37.39
3.5%
5 Jan 2023
Hamilton James C Chief Discovery/Trans Medicine
Sold, plan not stated 2×
$516.23K 13,803 at 37.40
6.7%
3 Jan 2023
O'Brien Patrick COO and General Counsel
Sold, plan not stated 8×
$670.80K 17,500 at 38.33
4.6%
3 Jan 2023
Hamilton James C Chief Discovery/Trans Medicine
Sold, plan not stated 8×
$396.74K 10,338 at 38.38
6.6%
29 Dec 2022
Myszkowski Kenneth Allen Chief Financial Officer
Sold, plan not stated
$1.23M 30,625 at 40.00
8.3%
21 Nov 2022
San Martin Javier Chief Medical Officer
Sold, plan not stated 2×
$584.74K 19,500 at 29.99
17.6%
11 Feb 2022
Anzalone Christopher Richard Chief Executive Officer
Sold, plan not stated 4×
$7.60M 146,388 at 51.91
3.5%
5 Jan 2022
Myszkowski Kenneth Allen Chief Financial Officer
Sold, plan not stated 4×
$2.47M 40,000 at 61.70
7.9%
5 Jan 2022
O'Brien Patrick General Counsel
Sold, plan not stated 5×
$2.01M 32,500 at 61.72
8.5%
5 Jan 2022
Hamilton James C Senior Vice President
Sold, plan not stated 5×
$385.77K 6,250 at 61.72
3.9%
4 Jan 2022
Hamilton James C Senior Vice President
Sold, plan not stated 5×
$1.27M 19,375 at 65.49
10.7%
3 Jan 2022
Sold, plan not stated 3×
$291.24K 4,500 at 64.72
14.9%
3 Jan 2022
PERRY MICHAEL S Director
Sold, plan not stated 3×
$291.19K 4,500 at 64.71
5.0%
3 Jan 2022
Sold, plan not stated 3×
$291.18K 4,500 at 64.71
20.9%
3 Jan 2022
Sold, plan not stated 3×
$262.23K 4,050 at 64.75
45.0%
28 Dec 2021
Ferrari Mauro Director
Sold, plan not stated
$227.19K 3,400 at 66.82
8.5%
28 Dec 2021
GIVEN DOUGLAS B Director
Bought
$43.47K 655 at 66.37
0.6%
First buy on file
15 Dec 2021
Anzalone Christopher Richard Chief Executive Officer
Sold, plan not stated 5×
$4.05M 60,000 at 67.56
1.8%
19 Nov 2021
San Martin Javier Chief Medical Officer
Sold, plan not stated 3×
$1.35M 19,500 at 69.31
14.9%
22 Oct 2021
Anzalone Christopher Richard Chief Executive Officer
Sold, plan not stated 2×
$3.28M 50,000 at 65.63
1.5%
20 Oct 2021
Anzalone Christopher Richard Chief Executive Officer
Sold, plan not stated
$993.45K 15,000 at 66.23
0.4%
13 Sep 2021
Sold, plan not stated 2×
$318.80K 5,000 at 63.76
35.7%
9 Sep 2021
GIVEN DOUGLAS B Director
Sold, plan not stated
$326.20K 5,000 at 65.24
4.4%
Showing 1–50 of 160. Page 1 of 4 Older →